Golimumab performs well in ankylosing spondylitis trial

02:00 EDT 13 Jun 2019 | Arthritis Digest

Intravenous golimumab, a biological drug, worked well during a one-year study in people with ankylosing spondylitis – and no new safety concerns were encountered – a team highlights in the Journal of Rheumatology. The research group randomly selected 105 people with active ankylosing spondylitis to be treated with 2mg per kg of intravenous golimumab. They […]

The post Golimumab performs well in ankylosing spondylitis trial appeared first on Arthritis Digest.

Original Article: Golimumab performs well in ankylosing spondylitis trial


More From BioPortfolio on "Golimumab performs well in ankylosing spondylitis trial"

Quick Search


Relevant Topics

Biological Therapy
Biological therapy involves the use of living organisms, substances derived from living organisms, or laboratory-produced versions of such substances to treat disease. Some biological therapies for cancer use vaccines or bacteria to stimulate the body&rs...

Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Arthritis Fibromyalgia Gout Lupus Rheumatic Rheumatology is the medical specialty concerned with the diagnosis and management of disease involving joints, tendons, muscles, ligaments and associated structures (Oxford Medical Diction...